Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Kintara Therapeutics, Inc. | ktra-10k_20200630.htm |
| EX-32.2 - EX-32.2 - Kintara Therapeutics, Inc. | ktra-ex322_242.htm |
| EX-32.1 - EX-32.1 - Kintara Therapeutics, Inc. | ktra-ex321_241.htm |
| EX-31.2 - EX-31.2 - Kintara Therapeutics, Inc. | ktra-ex312_240.htm |
| EX-31.1 - EX-31.1 - Kintara Therapeutics, Inc. | ktra-ex311_239.htm |
| EX-23.2 - EX-23.2 - Kintara Therapeutics, Inc. | ktra-ex232_310.htm |
| EX-21.1 - EX-21.1 - Kintara Therapeutics, Inc. | ktra-ex211_312.htm |
| EX-10.26 - EX-10.26 - Kintara Therapeutics, Inc. | ktra-ex1026_313.htm |
| EX-4.16 - EX-4.16 - Kintara Therapeutics, Inc. | ktra-ex416_309.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-1 No. 333-232332) of DelMar Pharmaceuticals, Inc. and in the related prospectus, |
|
|
(2) |
Registration Statement (Form S-1 No. 333-232931) of DelMar Pharmaceuticals, Inc. and in the related prospectus, |
|
|
(3) |
Registration Statement (Form S-3 No. 333-213600) of DelMar Pharmaceuticals, Inc. and in the related prospectus, and |
|
|
(4) |
Registration Statement (Form S-3 No. 333-229020) of DelMar Pharmaceuticals, Inc. and in the related prospectus; |
of our report dated September 9, 2019, with respect to the consolidated financial statements of Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) included in this Annual Report (Form 10-K) of Kintara Therapeutics, Inc. for the year ended June 30, 2020.
|
Vancouver, Canada, |
/s/ Ernst & Young LLP |
|
September 18, 2020 |
Chartered Professional Accountants |